Taking stock of the drug industry, from the lab to the medicine chestAugust 9, 2023Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Bloomberg STAT+ | Wegovy's successful heart trial raises a vital question about weight loss Researchers say the positive results don't prove that popular new obesity treatments improve heart health solely through weight loss. By Elaine Chen and Damian Garde 'Underwhelming': NIH trials fail to test meaningful long Covid treatments — after 2.5 years and $1 billion The NIH says it's used up most of its $1.15 billion of long Covid funding and more money is not forthcoming, per new budget details. By Betsy Ladyzhets STAT+ | Opinion: One way to create resilient drug supply chains: incentivize predictive models At the end of 2022, there were national shortages of 295 medications in the U.S. Predictive models can help. By Anna Sparrow Adobe Opinion: Public pharma is the best solution to the ongoing problem of drug shortages Publicly accountable public agencies can assure resilient supply chains and offer medicines at or even below cost. By Dana Brown and Christopher Morten Failed clinical trials don't always spell doom for a new drug. Here's why While a failed clinical trial might be bad news, it isn't always an automatic deal killer for a new drug, as STAT's latest report explains. By Erica Goode More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments